201 related articles for article (PubMed ID: 28761193)
1. Intranasal mast cell tumor in the dog: A case series.
Khoo A; Lane A; Wyatt K
Can Vet J; 2017 Aug; 58(8):851-854. PubMed ID: 28761193
[TBL] [Abstract][Full Text] [Related]
2. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001).
Gieger TL; Théon AP; Werner JA; McEntee MC; Rassnick KM; DeCock HE
J Vet Intern Med; 2003; 17(5):687-92. PubMed ID: 14529136
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE
J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome for MCTs of canine pinnae treated with surgical excision (2004-2008).
Schwab TM; Popovitch C; DeBiasio J; Goldschmidt M
J Am Anim Hosp Assoc; 2014; 50(3):187-91. PubMed ID: 24659731
[TBL] [Abstract][Full Text] [Related]
5. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998).
Hahn KA; King GK; Carreras JK
J Am Vet Med Assoc; 2004 Jan; 224(1):79-82. PubMed ID: 14710881
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002).
Cahalane AK; Payne S; Barber LG; Duda LE; Henry CJ; Mauldin GE; Frimberger AE; Cotter SM; Moore AS
J Am Vet Med Assoc; 2004 Aug; 225(3):401-8. PubMed ID: 15328716
[TBL] [Abstract][Full Text] [Related]
8. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision.
Weisse C; Shofer FS; Sorenmo K
J Am Anim Hosp Assoc; 2002; 38(1):71-3. PubMed ID: 11804319
[TBL] [Abstract][Full Text] [Related]
9. Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision.
Scarpa F; Sabattini S; Marconato L; Capitani O; Morini M; Bettini G
J Am Vet Med Assoc; 2012 May; 240(10):1181-7. PubMed ID: 22559107
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007).
Hume CT; Kiupel M; Rigatti L; Shofer FS; Skorupski KA; Sorenmo KU
J Am Anim Hosp Assoc; 2011; 47(1):37-44. PubMed ID: 21164163
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular mast cell tumors in 7 dogs.
Robinson WP; Elliott J; Baines SJ; Owen L; Shales CJ
Can Vet J; 2017 Sep; 58(9):931-935. PubMed ID: 28878416
[TBL] [Abstract][Full Text] [Related]
13. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001).
Sfiligoi G; Rassnick KM; Scarlett JM; Northrup NC; Gieger TL
J Am Vet Med Assoc; 2005 Apr; 226(8):1368-74. PubMed ID: 15844431
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors.
Jaffe MH; Hosgood G; Taylor HW; Kerwin SC; Hedlund CS; Lopez MK; Davidson JR; Miller DM; Paranjpe M
Vet Pathol; 2000 Jan; 37(1):40-6. PubMed ID: 10643979
[TBL] [Abstract][Full Text] [Related]
15. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
16. Cytologic Criteria for Mast Cell Tumor Grading in Dogs With Evaluation of Clinical Outcome.
Camus MS; Priest HL; Koehler JW; Driskell EA; Rakich PM; Ilha MR; Krimer PM
Vet Pathol; 2016 Nov; 53(6):1117-1123. PubMed ID: 27034386
[TBL] [Abstract][Full Text] [Related]
17. Principles of treatment for mast cell tumors.
Govier SM
Clin Tech Small Anim Pract; 2003 May; 18(2):103-6. PubMed ID: 12831070
[TBL] [Abstract][Full Text] [Related]
18. Iridium-192 interstitial brachytherapy as adjunctive treatment for canine cutaneous mast cell tumors.
Northrup NC; Roberts RE; Harrell TW; Allen KL; Howerth EW; Gieger TL
J Am Anim Hosp Assoc; 2004; 40(4):309-15. PubMed ID: 15238561
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors.
Ginn PE; Fox LE; Brower JC; Gaskin A; Kurzman ID; Kubilis PS
Vet Pathol; 2000 Jan; 37(1):33-9. PubMed ID: 10643978
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999).
Séguin B; Leibman NF; Bregazzi VS; Ogilvie GK; Powers BE; Dernell WS; Fettman MJ; Withrow SJ
J Am Vet Med Assoc; 2001 Apr; 218(7):1120-3. PubMed ID: 11318363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
